PCP
CORT icon

Perbak Capital Partners’s Corcept Therapeutics CORT Stock Holding History

Perbak Capital Partners’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-9,709
Closed -$391K – 63
2026
Q1 		$391K Buy
+9,709
New +$363K 0.1% 232

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Perbak Capital Partners's CORT Position: Q2 2026 in Review

Perbak Capital Partners sold out of Corcept Therapeutics (CORT) in Q2 2026, closing a stake of 9,709 shares — an estimated $391K sold.

Perbak Capital Partners first reported a position in CORT in Q1 2026 and held it in 1 quarter. The position peaked at $391K in Q1 2026. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Perbak Capital Partners reported no remaining Corcept Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Perbak Capital Partners sold 9,709 Corcept Therapeutics shares in Q2 2026, an estimated $391K.
  • Perbak Capital Partners first reported a position in Corcept Therapeutics in Q1 2026 and held it in 1 quarter.
  • Perbak Capital Partners's Corcept Therapeutics position peaked at $391K in Q1 2026.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Perbak Capital Partners's 13F filing for Q2 2026.